# Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)

> **NCT00889863** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 177 (actual)

## Conditions studied

- Systemic Juvenile Idiopathic Arthritis With Active Flare

## Interventions

- **DRUG:** canakinumab
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00889863
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 177 (ACTUAL)
- **Last updated:** 2012-10-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00889863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00889863, "Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT00889863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*